Kyle B. Stephenson
Ottawa, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: November 24, 2020
Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning.
Journal: Journal for immunotherapy of cancer
Published: July 22, 2020
Measles Vaccines Designed for Enhanced CD8+ T Cell Activation.
Journal: Viruses
Published: December 20, 2019
Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.
Journal: Nature communications
Published: July 23, 2019
Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
Journal: Journal for immunotherapy of cancer
Published: February 19, 2019
Development and applications of oncolytic Maraba virus vaccines.
Journal: Oncolytic virotherapy
Published: December 13, 2018
Endogenous T cells prevent tumor immune escape following adoptive T cell therapy.
Journal: The Journal of clinical investigation
Published: November 15, 2018
Transforming the prostatic tumor microenvironment with oncolytic virotherapy.
Journal: Oncoimmunology
Published: February 20, 2018
Separate roles of IL-6 and oncostatin M in mouse macrophage polarization in vitro and in vivo.
Journal: Immunology and cell biology
Published: August 12, 2017
Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats.
Journal: Scientific reports
Published: June 12, 2017
Last Updated: 09/26/2026